Skip to main content
Novartis
language-selector-globe United States | en
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe us
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Novartis in the US 
        • Diversity equity & inclusion  
        • Pay transparency-EPIC 
        • Our code of ethics 
      • Diversity, equity & inclusion  
        • Novartis US EEO / D&I report 2021 
        • Supplier diversity 
      • People and culture 
      • Products 
      • US Country Coordinating Committee 
      • External funding 
      • Contact us 
      Team meeting About
    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Patient assistance 
      • Diseases 
        • Chronic spontaneous urticaria (CSU) 
        • Hidradenitis suppurativa (HS) 
        • Prostate Cancer (PC) 
        • Paroxysmal Nocturnal Hemoglobinuria (PNH) 
      • Participating in clinical trials 
      • Patient perspectives 
      • Adverse event reporting 
      • The STEP program 
        • Sickle cell disease (SCD) 
        • Program overview 
        • Multiple sclerosis (MS) 
        • Cancer 
        • Application for funding to help address health disparities 
        • Health disparities 
      • Patient resources 
      Patient smiling at doctor image Patients and caregivers
    • Healthcare professionals 
      • Novartis pipeline 
      • Novartis clinical trials 
      • Adverse event reporting 
      • HCP resources 
      • Personalized and Precision Medicine 
      • Health Information Technology Resources 
      Two doctors examining X-ray Healthcare professionals
    • ESG 
      • Ethical behavior 
        • Code of ethics 
        • SpeakUp 
        • PhRMA Code on interactions with healthcare professionals 
        • Business principles 
      • Ethics, risk and compliance 
        • Compliance program 
        • State laws 
        • Corporate integrity agreement 
        • Payments to HCPs & HCOs 
        • Drug Supply Chain Security Act Information 
      • Corporate responsibility 
        • Population health 
        • Novartis in society US reports 
        • Novartis US Foundation 
        • Environmental sustainability 
        • People and communities 
      • Beacon of hope 
        • Beacon of hope: Measurable solutions for health equity 
        • Paving the way for a brighter, more equitable future 
      Novartis East Hanover Campus Landscaping ESG
    • News 
      • News archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting News
    • Careers 
      • Career search 
      • Meet the teams 
      • Early career 
      • Personal growth 
      • How we work 
      • Employee benefits 
      • Diversity, equity & inclusion 
      • Awards & recognition 
      Meeting in Atrium Careers
    Grandmother, mother and daughter smiling and laughing on a beach Home
  1. Home
  2. Careers
  3. Career Search
  • Sort by Sort ascending
  • Job Title
  • Site
  • Location
  • Division
  • Business
  • Functional Area Sort ascending
  • Date Posted
Job Title Site Location Division Business Functional Area Sort ascending Date Posted
QC Analyst III Tuas South Avenue Singapore Operations Innovative Medicines Quality Oct 03, 2024
AD, Patient Support Center - Program Monitoring Arizona USA US Innovative Medicines Quality Oct 04, 2024
Global GMP Expert Quality Auditor Mumbai (Head Office) India Operations Innovative Medicines Quality Oct 07, 2024
Labortechniker / QC Analyst II (m/w/d), Kundl, Tirol Kundl Austria Operations Innovative Medicines Quality Sep 26, 2024
QC Specialist II (m/w/d) Kundl, Tirol Kundl Austria Operations Innovative Medicines Quality Sep 26, 2024
Vodja skupine kontrole kakovosti v QLS Velike Molekule / Vodja laboratorija Bioanalitika (m/f/d), Mengeš Mengeš Slovenia Operations Innovative Medicines Quality Sep 27, 2024
Innovation Manager Hyderabad (Office) India Operations Innovative Medicines Quality Sep 30, 2024
QC Specialist I - Analytical Tuas South Avenue Singapore Operations Innovative Medicines Quality Sep 03, 2024
QC Specialist II - Analytical Tuas South Avenue Singapore Operations Innovative Medicines Quality Sep 03, 2024
QualityTeamLeader,QA Ops-Mfg Mgt(QA USP) Tuas South Avenue Singapore Operations Innovative Medicines Quality Sep 03, 2024
Associate Manager - Quality Operations Hyderabad (Office) India Operations Innovative Medicines Quality Sep 03, 2024
Specialist - Quality Operations Hyderabad (Office) India Operations Innovative Medicines Quality Sep 03, 2024
Specialist – Quality Operations Hyderabad (Office) India Operations Innovative Medicines Quality Sep 03, 2024
Specialist – QOP Hyderabad (Office) India Operations Innovative Medicines Quality Sep 03, 2024
Quality Control Team Coordinator İstanbul Kurtköy Turkey Operations Innovative Medicines Quality Sep 03, 2024
QC Specialist I - Raw Materials Tuas South Avenue Singapore Operations Innovative Medicines Quality Sep 05, 2024
AS&T ekspert (m/ž/d) Ljubljana Slovenia Operations Innovative Medicines Quality Sep 09, 2024
AS&T Expert (Micro) Tuas South Avenue Singapore Operations Innovative Medicines Quality Oct 01, 2024
Specialist upravljanja kakovosti I – skladnost / QA Compliance Specialist I (m/f/d), Mengeš Mengeš Slovenia Operations Innovative Medicines Quality Oct 02, 2024
Quality Control Specialist İstanbul Kurtköy Turkey Operations Innovative Medicines Quality Oct 02, 2024
Quality Assurance Specialist II Carlsbad USA Operations Innovative Medicines Quality Oct 02, 2024
QC Chemist Indianapolis USA Operations Innovative Medicines Quality Oct 08, 2024
Specialist-Quality Operations Hyderabad (Office) India Operations Innovative Medicines Quality Oct 08, 2024
Labortechniker / QC Analyst II (m/w/d), Tirol, Österreich Schaftenau Austria Operations Innovative Medicines Quality Sep 03, 2024
QC Specialist Tech Resources & Compliance Durham USA Operations Innovative Medicines Quality Sep 03, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Labortechniker / QC Analyst II im Mikrobiologischen Labor (m/w/d), Schaftenau, Tirol Schaftenau Austria Operations Innovative Medicines Quality Oct 23, 2024
AS&T Expert Schaftenau Austria Operations Innovative Medicines Quality Oct 24, 2024
Labortechniker / QC Analyst II (m/w/d), Schaftenau, Tirol Schaftenau Austria Operations Innovative Medicines Quality Oct 24, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Специалист по системе качества St. Petersburg (City) Russian Fed. Operations Innovative Medicines Quality Oct 22, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Senior Specialist DDIT OPS Mfg Site IT Sasayama Japan Operations CTS Information Technology Jul 22, 2024
Sr. Spec. DDIT IES Supplier Management Hyderabad (Office) India Operations CTS Information Technology Oct 18, 2024
Sr. Spec. IT Solution Delivery INSURGENTES Mexico Operations CTS Information Technology Jul 15, 2024
Government Affairs Manager Moscow (City) Russian Fed. Corporate Affairs Innovative Medicines Communications & Public Affairs Oct 22, 2024
Chef, Communications corporatives Montreal Canada Corporate Affairs CTS Communications & Public Affairs Oct 21, 2024
Associate Director, Political Affairs & Insights Washington, DC USA Corporate Affairs Corporate Communications & Public Affairs Oct 22, 2024
EA & Program Coordinator Beijing (Beijing) China Corporate Affairs Innovative Medicines Communications & Public Affairs Oct 22, 2024
Associate Director, Corporate Event Marketing East Hanover (New Jersey) USA Corporate Affairs CTS Communications & Public Affairs Oct 22, 2024
Manager, Corporate Communications Montreal Canada Corporate Affairs CTS Communications & Public Affairs Oct 21, 2024
Comms & Engagement Manager Amsterdam Netherlands Corporate Affairs CTS Communications & Public Affairs Oct 16, 2024
Executive Director, Therapy Area Communications and Patient Advocacy Basel (City) Switzerland Corporate Affairs CTS Communications & Public Affairs Oct 16, 2024

Pagination

  • ‹ Previous page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & caregivers
  • Healthcare professionals
  • ESG
  • News
  • Careers
Media center
  • News archive
  • Statements
  • Stories
Our portfolio
  • Novartis clinical pipeline
  • Novartis product portfolio
Other Novartis US websites
  • Oncology HCP resources
  • Medical information
  • Global site
Footer Bottom
© 2024 Novartis Pharmaceuticals Corporation
  • Terms of use
  • Privacy policy
  • Consumer health privacy policy
  • Contacts
  • Site map
  • Web accessibility
Novartis Site Directory
This site is intended for US residents only